Skip to content

A randomized, double bind, placebo-controlled study to evaluate the efficacy and safety of lorazepam on chest pain, delirium and cardiac arrhythmias in subjects with acute coronary syndrome

A randomized, double bind, placebo-controlled study to evaluate the efficacy and safety of lorazepam on chest pain, delirium and cardiac arrhythmias in subjects with acute coronary syndrome

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20161111001
Enrollment
300
Registered
2016-11-11
Start date
2016-08-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome patients

Interventions

comparison drug /placebo,comparison drug/placebo
Experimental Drug,Experimental Drug

Sponsors

siriraj hospital
Lead Sponsor
siriraj hospital
Collaborator

Eligibility

Sex/Gender
All
Age
15 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1. Acute Coronary Syndrome patients 2. Age>18 years 3. Stability and good consciousness 4. who can Thai communication

Exclusion criteria

Exclusion criteria: 1.Infection such as sepsis, urinary tract infection, pneumonia 2.Psychology abnprmality: Schizophrenia ,Dementia,or head injury :stroke,ICH or sleep apnea 3.History of sedation: Antianxiety Drugs/Anxiolytic Dug),antidepressant,anticonvulsan in 1 month before admission 4.severe hepatic and allergy of lorazepam 5.who can sleep 6.history of alcoholic,drug abuse 7.ผู้ป่วยตั้งครรภ์จากการซักประวัติ 8.ผู้ป่วยและ/ญาติไม่สมัครใจเข้าร่วมการศึกษา

Design outcomes

Primary

MeasureTime frame
chest pain 2017 double blind RCT

Secondary

MeasureTime frame
delirium 2017 double blind RCT,arrhythmias 2017 double blind RCT,satisfaction 2017 double blind RCT

Countries

Thailand

Contacts

Public Contactsaowanee Naowapanich

siriraj hospital

ning_ccu@hotmail.com024197751

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026